SOURCE: PharmaRoth Labs, Inc.

March 25, 2015 09:00 ET

PharmaRoth Labs Announces Endorsement by Mexican Diabetes Association

Sucanon® Proven to Be Safe & Effective Treatment

LAS VEGAS, NV--(Marketwired - Mar 25, 2015) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, is proud to announce that the Mexican Diabetes Association has endorsed Sucanon® as a safe and effective alternative treatment for pre-diabetic and recently diagnosed patients. The Mexican Association of Diabetes, AC, (AMD) is a nonprofit institution that provides care, education and training on diabetes care to people living with this disease and their families, in order to prevent the occurrence of the associated complications and provide them a better quality of life.

"The Mexican Diabetes Association is a wonderful organization that is focused on helping patients -- and their families or caregivers -- manage day to day life with diabetes," commented Luis Lopez, CEO of PharmaRoth. "We are very proud to have received this endorsement, as it is further validation that Sucanon® is a safe and effective tool for managing insulin levels, and gives us a great talking point for our upcoming marketing campaign in Mexico," Mr. Lopez went on to say.

For more information regarding Sucanon®, please visit

For more information about the Mexican Diabetes Association, please visit

About Sucanon®
Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.

About PharmaRoth
PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers' lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood pressure. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from estimates and are not guarantees of future performance. These statements may involve known and those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.

Contact Information

  • For investor relations contact:

    Michael Irving
    Paramount Advisors, LLC
    (407) 878-5462